Abstract Purpose: Oncostatin M (OSM) is an interleukin-6 cytokine family member, which inhibits cell proliferation and induces cell differentiation and apoptosis in cancers. In melanoma cells, epigenetic silencing of OSM receptor (OSMR) by histone deacetylation contributes to escape of cell growth control by OSM. However, the silencing of OSMR by DNA methylation in any cancer has not been examined. Experimental Design: Methylation status of OSMR was determined by sequencing or methylation-specific PCR in primary tumors and cell lines. Cell lines were treated with DNA methyltransferase inhibitors 5-aza-2-deoxycytidine or DNA methyltransferase 1 small interfering RNA or a histone deacetylase inhibitor trichostatin A. OSMR mRNA level was determined by reverse transcription-PCR.The acetylation of histone H3 was analyzed by chromatin immunoprecipitation assay. Results: We observed methylation of OSMR in 88 of 98 (90%) colorectal cancers, 34 of 38 (89%) colorectal polyps, 17 of 31 (55%) normal-appearing mucosa adjacent to colorectal cancers, 13 of 40 (33%) gastric cancers, and 2 of 10 (20%) pancreatic cancers. OSMR methylation was absent or rarely detected in normal colonic mucosa from noncancer patients or in cancers of nondigestive organs, including breast, lung, liver, prostate, kidney, and melanoma. We observed a significant correlation between OSMR methylation and loss of mRNA expression in 39 cancer cell lines. Following the treatment of colorectal cancer cell lines with 5-aza-2-deoxycytidine, DNA methyltransferase 1small interfering RNA, or trichostatin A, the induction of OSMR mRNA and the enrichment in the level of histone acetylation were observed. Conclusions: The epigenetic silencing and DNA methylation of OSMR occur frequently in colorectal cancers and rarely in cancers of nondigestive organs. OSMR methylation is an early event in the colorectal carcinogenesis.
Oncostatin M (OSM) is an interleukin-6 family cytokine produced mainly by activated monocytes and lymphocytes. This multifunctional cytokine induces growth inhibition, differentiation, and apoptosis in a variety of cancer cells, such as cancers of breast, ovary, lung, melanoma, and osteosarcoma (1 -6) . The biological effects of OSM are mediated through a heterodimeric complex of gp130 and OSM receptor (OSMR) by activation of either a signaling pathway involving Janus kinases and signal transducers and activators of transcription family (4, 7, 8) or a signaling pathway involving signal transducers and activators of transcription 5 and p53 (6) . The escape of cell growth control by OSM in metastatic melanoma cells has recently been reported to be caused by the epigenetic silencing of OSMR due to aberrant histone modification (9) . Although the lower level of OSMR in cancers has been reported, the promoter methylation of OSMR as a causal factor has not been examined.
In colorectal cancer, hypermethylation of tumor-associated genes is frequently present, such as SFRP1 to SFRP5 (10, 11) , TAC1, SST (12) , and SLC5A8 (13) as well as a group of genes that are methylated in cancers with CpG island methylator phenotype (14, 15) . To investigate whether epigenetic silencing of OSMR occurs in colorectal cancer, we determined the OSMR methylation status in colorectal cancer cell lines and primary colorectal cancers as well as cancers of other organs.
Materials and Methods
Cell lines and primary tumors. Colorectal cancer cell lines C, C1a, Caco2, Colo201, Colo320, H498, HCT8, HCT116, HRT18, HT29, Lovo, LS123, LS174T, RKO, RW2982, SW48, SW620, SW1116, SW1463, T74, VACO5, VACO6, VACO10P, VACO411, and VACO703; gastric cancer cell lines AgS and MgC; pancreatic cancer cell lines ASPC, CaP2, HPAC, HPAF, Hs766t, MiaPaCa, PANC, RWP1, SW1990, and UCVA; breast cancer cell lines BT20, BT474, MDA134, MDA157, MDA435, and SKBR3; lung cancer cell lines H82 and H146; and a prostate cancer cell line Du145 were obtained from the American Type Culture Collection. Cells were grown in DMEM supplemented with 10% fetal bovine serum at 37jC in 5% CO 2 atmosphere. Primary tumors, colorectal polyps, ulcerative colitis, and normal mucosa of colorectum and stomach were obtained at the University of California at San Francisco and Veteran Affairs Medical Center of San Francisco. This study was approved by the institutional review board. Samples were microdissected from formalinfixed, paraffin-embedded sections stained with H&E under a microscope as described previously (16) .
5-Aza-2 ¶-deoxycytidine, trichostatin A, and DNA methyltransferase 1 small interfering RNA treatment. Colorectal cancer cell line RKO was grown in 6-well plates on day 0 and treated with 1 Amol/L 5-aza-2-deoxycytidine (5-aza-dC; Sigma) on day 1 (passage 1, P1). The growth medium was replaced after 24 h (day 2). Cells were grown for 2 days before harvest or passage (day 4) as described (17) . Under this condition, the viabilities of cells were >70%. Cells were treated with 1 Amol/L 5-aza-dC again on day 5 (P2). The medium was replaced on day 6, and the cells were grown before harvest or passage on day 8. RKO cells were grown continuously from P3 to P5 without 5-aza-dC treatment. Colorectal cancer cell lines HT29, SW48, and VACO5 were also treated with 1 Amol/L 5-aza-dC twice and grown before harvest or passage with an interval of 5 to 8 days. RKO cells were treated with 300 nmol/L trichostatin A (TSA; Sigma) as described (17) . The medium was replaced after 24 h, and the cells were harvested 3 days after the removal of TSA. RKO cells were also treated with 100 nmol/L DNA methyltransferase 1 (DNMT1) small interfering RNA (siRNA; 5 ¶-AAGGAGAACGGTGCTCATGCT, dTdT) or 100 nmol/L control siRNA (Qiagen) in the presence of 8 AL/well Lipofectamine 2000 (Invitrogen) or 15 AL/well Oligofectamine (Invitrogen) in a 6-well plate. After incubation for 6 h, the growth medium was replaced. The cells were grown for 3 more days before harvest.
Growth inhibition assay. RKO cells were plated on 6-well plate on day 0. The untreated cells (control) were harvested on day 5. The 5-azadC-treated cells were treated with 1 Amol/L 5-aza-dC on day 1, growth medium was replaced on day 2, and cells were harvested on day 7. The OSM-treated cells were treated with 100 ng/mL OSM (Sigma) on day 1, replenished daily for 3 consecutive days until day 4, and harvested on day 5. The 5-aza-dC/OSM-treated cells were treated with 1 Amol/L 5-aza-dC on day 1, growth medium was replaced on day 2, and cells were treated with 100 ng/mL OSM on day 3, replenished daily until day 6, and harvested on day 7. The harvested cells were counted using a hemocytometer. Each group of cells, the control RKO cells (no treatment), cells treated with 5-aza-dC only, with OSM only, or with 5-aza-dC plus OSM were tested triplicately.
Methylation analysis. DNA obtained from cell lines, tumors, or noncancer tissues was modified with NaHSO 3 (17) . Primer sequences used for methylation analysis of OSMR were obtained from GenBank NM 003999. DNA methylation status of OSMR was determined by sequencing (18) or by methylation-specific PCR (MSP; ref. 17) . For sequencing, three sets of primers were used to amplify the NaHSO 3 -modified DNA, which covered the main part of CpG island (-382 to +72, relative to the start of transcription): SF1 5 ¶-GGGATGA-TAAGTGTTTTTGTGGGATAT and SR1 5 ¶-CAACCCRAACTTTACRAA-CRAACRAACAC, SF2 5 ¶-GGAGTTTYGGTYGTYGAGTTTTYGGTTTTT and SR2 5 ¶-TCCCRTCTTACTACRCACTCTTAAC, and SF3 5 ¶-GGGATT-GAAGGGAGGGAATTT and SR3 5 ¶-CTCACRCCRCRAACRAAAAACTCC. For MSP analysis, the NaHSO 3 -modified DNA was preamplified by PCR with three sets of primers, which amplified both methylated and unmethylated sequences in three separate regions: . Methylation status of SFPR1, TAC1, SST, SLC5A8, MGMT, and hMLH1 genes was analyzed as described previously (19) .
Determination of OSMR mRNA expression. RNA from cell lines was reverse transcribed, and the cDNA was amplified by PCR (18) using a primer set spanning exons 1 to 3 of the OSMR gene: F 5 ¶-CCTACCTGAAAACCAGAACTGATG and R 5 ¶-CAGGAGTCAATGG-TAAACGTTCAG.
Mutation analysis of p53 gene. Genomic DNA of tumors was amplified by PCR using four primer sets covering exons 5 to 8 of the p53 gene (19) . The PCR products were sequenced with an ABI PRISM 3100 automated sequencer.
Determination of acetylated histone H3 in the chromatin of OSMR region by chromatin immunoprecipitation assay. Chromatin immunoprecipitation assay was done using a chromatin immunoprecipitation kit (Upstate Biotechnology) and following the manufacturer's procedure (17) . Cells were treated with 1% formaldehyde, washed with PBS, and lysed in SDS lysis buffer. The cross-linked chromatin was sheared by sonication and precipitated with anti-acetylated histone H3 antibody (Upstate Biotechnology) at 4jC overnight. After the antibody/histone/ DNA complex was purified by salmon sperm DNA/protein A agarose slurry, the histone-DNA cross-linking was reversed by heating at 65jC, and DNA was recovered by proteinase K digestion, phenol extraction, and ethanol precipitation. DNA was amplified by PCR separately with primers of h-actin (5 ¶-TCACCAACTGGGACGACATG and 5 ¶-ACCGGAGTCCATCACGATG) and OSMR (5 ¶-ATGACAAGTGCCCC-TGTG and 5 ¶-AGCCTCACAACCCGGACTTT) covering the 5 ¶ upstream region (from -423 to -193). The PCR products were separated on a 2% agarose gel. The density of each band was measured with a densitometer. The ratio of density from antibody-precipitated chromatin DNA over that from input control (chromatin DNA collected before antibody-precipitation) indicates the level of the acetylated H3.
Translational Relevance
In this study, we observed methylation of oncostatin M receptor (OSMR) gene in 90% colorectal cancers, 33% gastric cancers, and 20% pancreatic cancers but rarely in normal colonic mucosa from noncancer patients or in cancers of nondigestive organs.We also observed that methylation of OSMR was significantly correlated with the loss of mRNA expression in cancer cell lines and that the treatment of cancer cells with DNA methyltransferase inhibitors induced OSMR mRNA expression and inhibited cell growth rate. The presence of OSMR methylation in 89% premalignant colorectal polyps and 55% normal-appearing colonic mucosa adjacent to cancer indicates that methylation of OSMR gene is an early epigenetic event in colorectal carcinogenesis. This unique pattern of OSMR methylation in cancers of colorectum and other digestive organs may be potentially beneficial in early diagnosis and development of targeted epigenetic therapy in these cancers.
Statistical analysis. Comparison of categorical variables was made using m 2 test. Student's t test was used for comparison of mean age of patients and mean cell number after treatment with 5-aza-dC and OSM. For all the statistical analyses, P < 0.05 was regarded as statistically significant.
Results
Methylation of OSMR in cancer cell lines determined by sequencing. Methylation of 49 CpG sites in the -382 to +72 region of OSMR was determined by NaHSO 3 sequencing analyzing in 25 colorectal cancer cell lines, 2 gastric cancer cell lines, 10 pancreatic cancer cell lines, 6 breast cancer cell lines, 2 lung cancer cell lines, and 1 prostate cancer cell line. Figure 1A summarizes the methylation status of OSMR promoter in 7 colorectal cancer cell lines, 2 gastric cancer cell lines, 1 breast cancer cell line, and 1 prostate cancer cell line. Methylation was observed in all 7 colorectal cancer cell lines. The region with high rates of methylation (60-100%) was located at -382 to -102 for each of the 7 cell lines, whereas, in the more proximal region (from -64 to +39), methylation rate was decreased to 10% to 60% in 3 of 7 colorectal cancer cell lines. The methylation rates of the gastric cancer cell lines AgS and MgC, breast cancer cell line BT474, and prostate cancer cell line Du145 were 1% to 5% in the region from -382 to +72. The samples with average methylation rate of >60% in the region of -382 to -102 were scored as methylation positive. Methylation was positive in 24 of 25 (96%) colorectal cancer cell lines, whereas methylation was detected in only 1 of 10 (10%) pancreatic cancer cell lines and was not observed in 2 gastric cancer cell lines, 6 breast cancer cell lines, 2 lung cancer cell lines, and 1 prostate cancer cell line.
Correlation of loss of expression with methylation of OSMR gene. RNA was obtained from 23 colorectal cancer cell lines, 10 pancreatic cancer cell lines, and 6 breast cancer cell lines. The mRNA level of OSMR was determined by reverse transcription-PCR with h-actin as an internal control. Table 1 summarizes the mRNA expression and the methylation status of OSMR in each cell line. Twenty-one of 23 (91%) cell lines with methylated OSMR did not express mRNA, whereas all 16 cell lines with unmethylated OSMR expressed mRNA. The observed significant correlation between loss of OSMR mRNA expression and methylation of OSMR (P < 0.001, m 2 test) indicated that methylation of OSMR silenced OSMR gene transcription.
OSMR mRNA was induced and acetylation of histone H3 was enriched by the treatment of 5-aza-dC, TSA, or DNMT1 siRNA. The methylation levels of OSMR promoter were decreased after RKO cells were treated with 5-aza-dC twice at P1 and P2 ( Fig. 2A) . A significant induction of the mRNA of OSMR was also observed following the treatment with demethylating agent 5-aza-dC, histone deacetylase inhibitor TSA, or DNMT1 inhibitor DNMT1 siRNA ( Fig. 2A and B) . After RKO cells were treated twice with 5-aza-dC (at P1 and P2), the highest levels of OSMR mRNA were detected, and the induced expression was gradually decreased after 5-aza-dC was removed (P3-P5; Fig. 2A ). The induction of OSMR mRNA was also observed in colorectal cancer cell lines HT29, SW48, and VACO5 after 5-aza-dC treatment (data not shown). When DNMT1 was inhibited by siRNA, the induction level of OSMR (6), and SW1463 (7), gastric cancer cells lines AgS (8) and MgC (9), breast cancer cell lines BT20 (10) and BT474 (11) , and prostate cancer cell line Du145 (12) was determined by MSP. M, methylation bands; U, unmethylation bands. C, methylation status of 12 colorectal cancers was determined by MSP. The methylation-specific and unmethylation-specific amplicons were loaded in a pair of wells with top to bottom alignment (B and C).
mRNA was higher using Oligofectamine as a transfection agent than using Lipofectamine 2000 (Fig. 2B) . The efficiencies of DNMT1 knockdown by siRNA were determined by DNMT1 mRNA expression level after the treatment of siRNA. DNMT1 mRNA levels in siRNA-treated RKO cells was only 25% and 10% (in the presence of Lipofectamine 2000 and Oligofectamine, respectively) of those in the control cells, indicating that 75% to 90% of the DNMT1 expression was knocked down. The OSMR mRNA was also induced by TSA (Fig. 2B) . The treatment of RKO cells with 5-aza-dC and TSA enriched the levels of histone acetylation (Fig. 2C) . The ratio of the intensity of the PCR band from anti-acetylated H3-precipitated chromatin over the intensity of the PCR band from the input control is indicative of the level of acetylated H3. The levels of acetylated H3 in the h-actin region were similar among RKO cells with no treatment, treatment with 5-aza-dC, or treatment with TSA (1.1, 0.9, and 1.0, respectively). However, the acetylated H3 levels in the OSMR region of RKO cells without treatment was very low (0.05) compared with the acetylated H3 levels in RKO cells treated with 5-aza-dC or TSA, which showed marked increase (0.9 or 1.4, respectively).
Demethylation of OSMR restored the cell growth inhibition by OSM. Colorectal cancer cell line RKO was grown in 6-well plate and treated with OSM, 5-aza-dC, or 5-aza-dC plus OSM. The cell numbers were counted after the treatment (Fig. 2D) . The slightly decreased cell number after 5-aza-dC treatment indicates the cytotoxic effect under this condition. OSM treatment did not inhibit the growth of RKO cells (P value between control and OSM-treated cells was not significant), showing that the OSM signaling may be interrupted by the lack of OSMR expression caused by promoter methylation in RKO cells (9) . However, after the treatment with 5-aza-dC, OSM did inhibit the cell growth (Fig. 2D) . The P value between 5-azadC-treated and 5-aza-dC/OSM-treated cells was 0.012. These results indicated the role of OMSR in the cell growth inhibition signaling by OSM and also that induction of OSMR expression by demethylation caused inhibition of cell growth in colorectal cancer cells with methylated OSMR. Methylation of OSMR in cancer tissues determined by MSP. Primer sets MF2/MR2 and UF2/UR2 used in MSP cover the region from -282 to -224 in the OSMR promoter, where a high percentage of methylation was observed in all 7 colorectal cancer cell lines and no methylation was found in 2 gastric cancer, 1 breast cancer, and 1 prostate cancer cell lines by sequencing (Fig. 1A) . We first analyzed the methylation status by MSP in 7 colorectal cancer cell lines, which showed methylation of OSMR by sequencing (C1a, Caco2, Colo320, LS174T, RKO, SW48, and SW1463), and 5 other cancer cell lines, which showed no methylation by sequencing (AgS, MgC, BT20, BT474, and Du145; Fig. 1B ). In all cell lines, the methylation status determined by MSP was consistent with the methylation status determined by sequencing, indicating that MSP is a reliable method. For the determination of the methylation status of OSMR in the tissue samples, the DNA from the samples was preamplified using primers MUF2/MUR2 and the methylation of the preamplified products was determined by MSP using methylation-specific and unmethylation-specific primer sets, MF2/MR2 and UF2/UR2, through only 20 cycles of PCR. Under this condition, the PCR products were linearly proportional to the PCR cycle number, enabling us to obtain quantitative data. Figure 1C shows that 8 of 12 colorectal cancers showed methylation of OSMR. In 7 of these 8 positive samples, OSMR was partially methylated. The partial methylation in 4 samples and complete methylation in 1 sample were confirmed by sequencing. The partial methylation detected in the tumor tissues might be due to either contamination by normal stroma cells or hemimethylation of OSMR. The CpG islands in OSMR gene cover an area with 1.3 kb in length from -960 to +360. A previous study showed that a region from -693 to +229 was active in transfective experiment when inserted upstream of luciferase gene (9) . To clarify the methylation status in this active region, we also measured the methylation in more upstream and more downstream regions of the central part by MSP. The methylation status in 19 colorectal cancer cell lines and 25 colorectal cancer tissues was identically positive in all three regions. When 16 normal colonic mucosa from noncancer patients and 10 breast cancers were tested, methylation was negative in all three regions, indicating that the methylation status of each CpG site in the whole CpG islands is stable. Thus, we only analyzed the methylation in the central region by MSP in later experiments. (33%) gastric cancers and 2 of 10 (20%) pancreatic cancers], and rarely in cancers of other organs, including liver, breast, lung, prostate, kidney, and melanoma. Methylation of OSMR was rarely observed in normal colonic mucosa, ulcerative colitis, normal gastric mucosa, and WBC. In colorectal polyps including 10 hyperplastic polyps, 10 serrated adenomas, 10 tubulovillous adenomas, and 8 tubular adenomas, OSMR methylation was observed in 10 (100%), 9 (90%), 10 (100%), and 5 (63%) cases, respectively ( Table 2) .
Seventeen of 35 colorectal cancers showed OSMR methylation in both cancers and the adjacent normal mucosa, whereas 14 cases showed OSMR methylation only in cancers and 4 cases showed no methylation in either cancer or the adjacent mucosa (Table 3) . When these three groups of cases with varying degrees of OSMR methylation in cancers and the adjacent normal mucosa were compared, significant correlation was observed between OSMR methylation status and p53 mutation (P = 0.026). Only 29% of the cases with methylated OSMR in both cancers and adjacent mucosa carried p53 mutation, whereas 57% of the cases with methylated OSMR only in cancers and 100% of the cases with unmethylated OSMR in both cancers and adjacent mucosa showed p53 mutation ( Table 3 ). The OSMR methylation status in three groups also significantly correlated with age at diagnosis (65.9, 74.4, and 84.3, respectively; P = 0.032; Table 3 ). The OSMR methylation status in these three groups did not show significant correlation with other clinical and molecular characteristics of the tumor, including gender, tumor stage, 5-year survival, tumor location (Table 3) , microsatellite instability, CpG island methylator phenotype, loss of heterozygosity, and mutations of BRAF and KRAS genes (data not shown).
Comparison of methylation frequency of OSMR with other tumor-associated genes. Because the OSMR gene was frequently methylated in colorectal cancer, less frequently methylated in gastric and pancreatic cancers, and rarely methylated in other cancers, we wished to compare the methylation frequencies of other tumor-associated genes, which are frequently methylated in colorectal cancer. We recently reported that methylation of SFRP1, TAC1, SST, SLC5A8, MGMT, and hMLH1 occurs in colorectal cancers with frequencies of 100%, 97%, 91%, 81%, 59%, and 14%, respectively, in our previous study (19) . Using the same technique, we determined the methylation of these genes in primary cancers of colorectum (74 cases), stomach (12 cases), pancreas (10 cases), liver (10 cases), breast (12 cases), lung (11 cases), prostate (6 cases), kidney (10 cases), and melanoma (6 cases; Fig. 3 ). The methylation frequency profile of OSMR within cancers of nine different organs was different from the methylation profiles of six other tumor-associated genes. OSMR showed very frequent methylation in colorectal cancer, less frequent methylation in gastric and pancreatic cancer, and very rare or not methylated in other cancers, whereas methylation of SFRP1, TAC1, SST, SLC5A8, and MGMT genes was very frequently or frequently present in cancer of almost all organs tested.
Discussion
As a member of the interleukin-6 cytokine family, OSM inhibits cell proliferation and induces cell differentiation and apoptosis in cancer cells. The heterodimer of OSMR and pg130 specifically mediates these biological effects through the Janus kinase/signal transducers and activators of transcription pathway (4, 7, 8) . The lost or decreased expression of OSMR has been reported in metastatic melanoma and has been shown to be caused by histone deacetylation (9) . Because both DNA Fig. 3 . Methylation frequency of OSMR, SFRP1,TAC1, SST, SLC5A8, MGMT, and hMLH1genes in primary tumors of colorectal, gastric, pancreatic, liver, prostate, kidney, lung, and breast cancers and melanoma. Research.
on August 6, 2017. © 2009 American Association for Cancer clincancerres.aacrjournals.org Downloaded from methylation and histone modification suppress the transcription of tumor-associated genes, we sought to investigate the methylation status of OSMR in cancers. In this study, we observed a very frequent methylation of OSMR in colorectal cancer and less frequent methylation in gastric and pancreatic cancers but rare methylation in cancers of other organs. The induction of OSMR expression and the enrichment of histone acetylation in chromatin after treatment with demethylation agents 5-aza-dC, DNMT1 siRNA, or a histone deacetylase inhibitor TSA indicated that epigenetic events regulating OSMR transcription play important roles in OSM signaling in colorectal cancer and other cancers of the digestive system. The silencing of OSMR by DNA methylation was also confirmed by a significant correlation between DNA methylation and loss of mRNA expression in 23 colorectal cancer cell lines, 10 pancreatic cancer cell lines, and 6 breast cancer cell lines. However, methylation may not be the only event in gene regulation. In two cell lines with high levels of OSMR gene expression, Caco2 and PANC, methylation was present in CpG islands including upstream, central, and downstream regions determined by sequencing and MSP.
Colorectal cancer arises from the accumulation of genetic and epigenetic aberrations, such as mutations of APC, p53, BRAF, or KRAS genes, chromosomal abnormalities, DNA methylation, and global hypomethylation, indicating the molecular heterogeneity of this disease. However, colorectal cancer frequently shows some common epigenetic aberrations, such as methylation of SFRP1 (10, 11, 19, 20) , TAC1, SST (12, 19) , and SLC5A8 (13, 19) , which occur in >80% of colorectal cancers, regardless of the CpG island methylator phenotype status. In this study, we showed that the methylation frequencies of these genes are also high in cancers of other organs, whereas OSMR methylation occurs very frequently in colorectal cancer, less frequently in gastric and pancreatic cancers, and rarely in cancers of other organs. This unique pattern of OSMR methylation observed in colorectal cancer and other digestive tract cancers suggests an organ-specific abnormality in signaling and pathways of carcinogenesis, and this observation can be potentially beneficial for the development of novel approaches to early diagnosis and targeted therapy for these cancers.
Several studies have shown the high rates of methylation and CpG island methylator phenotype in colorectal adenomas, especially in serrated adenoma, sessile serrated adenoma, and villous adenoma (21 -24) . In the present study, OSMR methylation was frequently observed in colorectal polyps, including hyperplastic polyps (100%), serrated adenoma (90%), tubulovillous adenoma (100%), and tubular adenoma (63%), indicating that OSMR methylation occurs early in colorectal carcinogenesis. Patients with ulcerative colitis have been reported to be at increased risk for developing colorectal cancer due to repetitive mucosal injury (25, 26) . However, OSMR methylation was not detected in any of 40 ulcerative colitis cases, indicating that its carcinogenesis pathway might be different from the polyps-carcinoma sequence pathway (23, 24) . This is consistent with the observations that ulcerative colitis-associated cancers showed less frequent CpG island methylator phenotype and higher p53 mutation rates than sporadic colorectal cancers (25, 26) .
In this study, we found frequent methylation of OSMR in the normal-appearing mucosa adjacent to the colorectal cancer with methylated OSMR (55%), indicating that OSMR methylation may be one of the mediators of field effect or field cancerization in the colorectal mucosa. Together with our data on OSMR methylation in polyps, our data indicate that OSMR methylation occurs early in multistep carcinogenesis before the morphologic changes occur in colorectal mucosa. A similar result has been reported with MGMT methylation in adjacent normal mucosa, indicating that alterations in the DNA methylation pattern of certain genes may potentially contribute to field effect (27) . Our observation that OSMR methylation status in both cancers and adjacent mucosa correlates with wild-type p53 and younger age at diagnosis suggests that OSMR methylation occurs early in colorectal carcinogenesis. This observation may be explained in part by the induction of p53 by OSM, which together contribute to the activation of apoptotic pathways during the progression of colorectal cancer (6) .
In summary, to our knowledge, this is the first report that OSMR methylation and loss of OSMR expression occur frequently in colorectal cancer, and to a lesser extent in gastric and pancreatic cancers, but rarely in cancers of other organs. Furthermore, OSMR methylation occurs frequently in colorectal polyps and the adjacent normal-appearing mucosa, indicating that it is an early event in colorectal carcinogenesis. Our observations that OSMR methylation in colorectal cancer cells is closely associated with loss of mRNA expression and that treatment with demethylation agent 5-aza-dC or histone deacetylase inhibitor TSA restores OSMR mRNA expression and growth inhibition effect of OSM indicate that epigenetic events play important role in the regulation of OSM signaling in colorectal cancer cells. Together, our results indicate that promoter methylation of OSMR appears to play important role early in colorectal carcinogenesis, and the epigenetic therapy targeted to methylated OSMR may be helpful in the prevention and therapy of colorectal cancers and other digestive tract tumors.
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